BPC-157 vs TB-500: Differences in Research Applications

BPC-157 is a 15-amino acid synthetic peptide with the molecular formula C62H98N16O22 and a molecular weight of 1419.53 g/mol. It is derived from a protein found in human gastric juice and is produced via solid-phase peptide synthesis.

TB-500 is a synthetic analogue of Thymosin Beta-4, a naturally occurring 43-amino acid protein. The research-use fragment has a molecular weight of 4963.5 g/mol — significantly larger than BPC-157.

In-vitro studies involving BPC-157 have primarily examined its interactions with fibroblast cell lines and its behaviour in musculoskeletal cell signalling models. Research has also investigated its effects on nitric oxide system activity in isolated cell preparations and gastrointestinal epithelial cell models.

TB-500 research has focused primarily on cell migration and cytoskeletal organisation. The peptide's interaction with actin — specifically the G-actin monomer — has been characterised in several structural biology studies. Research has examined endothelial cell migration assays and keratinocyte behaviour in cell culture models.

The two peptides target different cellular mechanisms, which is why they are frequently studied in combination. Their different molecular weights and sequences mean they interact with distinct receptor systems, making them useful for comparative studies.

Both compounds are supplied as white lyophilised powder and require identical storage conditions: -20°C, desiccated, away from light. Both degrade rapidly at room temperature and should be reconstituted immediately prior to experimental use.

Neither BPC-157 nor TB-500 is approved for human use by any regulatory authority. Both are sold strictly for in-vitro laboratory research purposes only.